Primary antibiotic resistance in Helicobacter pylori in China: a systematic review and meta-analysis

• Published in: Journal of global antimicrobial resistance. 2023-09, Vol.34, p.30-38
• Main Authors: Wang, Yuxiang, Du, Jinran, Zhang, Dayan, Jin, Cong, Chen, Jiangpo, Wang, Zeyuan, Mei, Tonglin, Fu, Kaili, Qian, Qingzeng, Pang, Tieliang
• Format: Article
• Language: English
• Subjects: China; Drug resistance; Helicobacter pylori; Meta-analysis
• ISSN: 2213-7165; 2213-7173
• DOI: 10.1016/j.jgar.2023.05.014

•Primary antibiotic resistance in Helicobacter pylori in China was analyzed.•Resistance to four main Helicobacter pylori antibiotics was analyzed.•The prevalence of resistance to these four antibiotics requires attention. The incidence of Helicobacter pylori (HP) is 25–50% in developed countries and 80% in developing countries, including 56.2% in China. However, antibiotic resistance of HP is a threat to HP control. The purpose of this study was to comprehensively evaluate primary drug resistance of HP in China. The full text of reports of the primary antibiotic resistance prevalence of HP was obtained from multiple databases (PubMed, Web of Science, Evimed, Cochrane Library, and China National Knowledge Internet). Review Manager 5.2 was adopted for meta-analysis, sensitivity analysis, and bias analysis. The Newcastle-Ottawa Scale was used to assess the article quality. In total, 38804 HP samples from 22 trials were extracted. The results suggested that the overall prevalence of amoxicillin, clarithromycin, metronidazole, and levofloxacin resistance among HP in adults was as follows: mean difference (MD) = 1.35%, 95% confidence interval (CI) [1.03%, 1.68%]; MD = 23.76%, 95% CI [20.23%, 27.3%]; MD = 69.32%, 95% CI [64.85%, 73.8%]; and MD = 29.45%, 95% CI [4.90, 176.96], respectively. From the results of sensitivity and publication bias, we find that these results are robust and had little publication bias. Our research showed that in China, the prevalence of HP resistance to primary antibiotics warrants attention, especially with regard to metronidazole, levofloxacin, and clarithromycin.